South Korea Ministry of Food and Drug Safety approved Novavax COVID-19 vaccine
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
Novavax and Serum Institute filed for Emergency Use Authorization of Novavax’ COVID-19 vaccine in South Africa
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
First successful transplant of porcine heart into adult human with end-stage heart disease
On Jan. 10, 2022, in a first-of-its-kind surgery, a 57-year-old patient with terminal heart disease received a successful…
Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in India
On Dec. 28, 2021, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
Development of WRAI’s pan-coronavirus vaccine showed promise
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
Novavax and SK bioscience announed expanded manufacturing agreement
On Dec. 23, 2021, Novavax and SK bioscience announced the expansion of the companies’ collaboration and license agreements…
Novavax announced initial Omicron cross-reactivity data from COVID-19 vaccine booster and adolescent studies
On Dec. 22, 2021, Novavax announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against…
Novavax announced initiation of PREVENT-19 COVID-19 vaccine phase 3 trial booster study
On Dec. 21, 2021, Novavax announced that the first booster doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based…
World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
European Commission granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the European Commission (EC) had granted Novavax conditional marketing authorization (CMA)…
Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine
On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…
Novavax filed for Emergency Use of COVID-19 vaccine in the United Arab Emirates
On Dec. 13, 2021, Novavax announced that it had submitted a regulatory filing to the Ministry of Health…
Novavax filed for interim authorization of COVID-19 vaccine in singapore
On Nov. 24, 2021, Novavax announced its submission to the Singapore Health Sciences Authority for interim authorization of…
Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in the Philippines
On Nov. 17, 2021, Novavax and and Serum Institute of India announced that the Philippine Food and Drug…
Novavax confirmed European Medicines Agencyreview of COVID-19 vaccine filing for Conditional Marketing Authorization
On Nov. 17, 2021, Novavax announced that the European Medicines Agency (EMA) had begun its evaluation of an…
Zosano Pharma announced successful formulation of COVID-19 vaccine candidate on its microneedle patch system
On Nov. 17, 2021, Zosano Pharma announced that the Philippine Food and Drug Administration had granted emergency use…
Imported Monkeypox case reported in Maryland
On Nov. 17, 2021, scientists at the Centers for Disease Control and Prevention (CDC) announced they were collaborating…
Novavax announced submission of Biologics License Application in South Korea for approval of NVX-CoV2373
On Nov. 15, 2021, Novavax and SK bioscience announced submission of a Biologics License Application (BLA) for Novavax’…
Long-term study of children with COVID-19 began
On Nov. 15, 2021, a large, long-term study of the impacts of COVID-19 on children announced it had…
COVID-19 | Nanotechnology | Vaccine | WHO
Novavax filed COVID-19 vaccine for Emergency Use listing with World Health Organization
On Nov. 4, 2021, Novavax announced the completion of its rolling submission to the World Health Organization (WHO)…
Novavax filed COVID-19 vaccine for provisional approval in New Zealand
On Nov. 3, 2021, Novavax announced the company had filed for provisional approval of the vaccine to the…
Novavax filed for COVID-19 vaccine authorization with Health Canada and completed submission to EMA
On Nov. 1, 2021, Novavax announced the completion of its rolling submission to Health Canada for authorization of…
Novavax and Serum Institute of India receive Emergency Use Authorization for COVID-19 vaccine in Indonesia
On Nov. 1, 2021, Novavax and Serum Institute of India announced that the National Agency of Drug and…
Novavax filed for provisional approval of its COVID-19 vaccine in Australia
On Oct. 29, 2021, Novavax announced the completion of its rolling submission to the Therapeutic Goods Administration (TGA)…
Novavax filed for authorization of its COVID-19 vaccine in the United Kingdom
On Oct. 27, 2021, Novavax announced the completion of its rolling regulatory submission to the U.K. Medicines and…
Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine
On Sept. 23, 2021, Novavax with its partner, Serum Institute of India announced a regulatory submission to the…
Results from Novavax NanoFlu influenza vaccine phase 3 clinical trial Published in The Lancet Infectious Diseases
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
Novavax included in University of Oxford Com-COV3 study comparing mixed COVID-19 vaccine in adolescents
On Sept. 16, 2021, Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing…
Novavax initiated phase 1/2 clinical trial of combination vaccine for COVID-19 and seasonal influenza
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…